Navigation Links
Siemens Introduces Its New Generation of Artis Interventional Imaging Systems
Date:11/25/2007

image processing and documentation - that delivers sharply detailed images required for interventional procedures, enhances clarity in 2D imaging, and enables an array of 3D imaging applications to help enhance clinical decision-making.

"The introduction of the Artis zee family brings enhanced versatility to drive workflow improvements that can help meet the increasing volume in interventional procedures, no matter what the clinical setting," said Claus Grill, vice president, Angiography, Cardiac, and X-ray Systems, Siemens Medical Solutions. "From the innovation of the Artis zeego to imaging excellence of 3D applications like syngo DynaCT, Siemens is uniquely positioned to meet the burgeoning demands of the interventional radiology field as they continue to evolve."

New and enhanced 3D imaging applications included with the Artis zee systems include:
-- syngo iPilot, which enables faster, more precise catheter navigation

through 3D roadmapping that superimposes 3D reconstructions onto live

2D fluoroscopy images, 2D roadmaps or digital subtraction angiography

(DSA). The application provides real-time updates of C-arm and table

movements, as well as zoom and source-to-image distance (SID) changes.

-- syngo iGuide, which is designed to brings needle procedures back into

the interventional suite, enabling enhanced comfort for the physician

and freeing up the computed tomography (CT) scanner from this lengthy

procedure. With the superb fluoroscopy image quality of the Artis zee

systems, these procedures can be executed faster and with greater

confidence.

The Artis zee systems are designed to streamline workflows and create efficiencies to help keep pace with increased interventional volume. Intuitive, menu-driven workflows streamline such procedures as obtaining soft tissue results for both frequent and infrequent users. The Artis zee systems also enable
'/>"/>

SOURCE Siemens Medical Solutions
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
2. Siemens Extends Tender Offer for Acquisition of Dade Behring
3. Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award
4. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
5. VIDEO from Medialink and Siemens: The Next Generation Allergy Test - Nothing to Sneeze At
6. Siemens Building Technologies Pioneers Wireless Solution for St. Anthonys Sensitive Environment
7. Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. VIDEO from Medialink and Siemens: Worlds Smallest Ultrasound Package Launches in the U.S.
10. Siemens Soarian Health Information Management is Widely Adopted by Leading Healthcare Institutions in 2007
11. James Cracknell Launches Siemens Stroke for Stroke Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/23/2014)... to the bottom of Alzheimer,s disease has been ... and controversies. In the latest crook in the ... into the interaction between proteins associated with the ... ACS Chemical Neuroscience , could have important ... Surewicz, Krzysztof Nieznanski and colleagues explain that for ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... UT Southwestern Medical Center are making breakthroughs that could ... A team of physician-scientists at UT Southwestern has identified ... natural anti-depressant properties) works inside the brain. Simultaneously, the ... in the form of a neuroprotective drug known as ... April,s issue of Molecular Psychiatry, is notable ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3
... in no real danger, survey finds , MONDAY, Aug. 20 ... white peers to take risks that boost their odds for ... August issue of the journal Archives of Dermatology , ... Medicine surveyed 369 high school students (221 white Hispanics and ...
... are exposed to more pro-tobacco advertising, according to a ... this months Public Health Reports. , Smoking remains ... the United States, causing more than 440,000 deaths annually ... indirect costs each year; African-Americans currently bear the greatest ...
... In a study likely applicable to men of other ... than 21 drinks per week) may increase the risk ... study are published in the latest issue of Annals ... Lydia Bazzano of Tulane University School of Public Health ...
... sounds like the latest cleaning sensation being hawked on ... get in your eyes. , But a few properly ... to diagnosing dry eye syndrome earlier than other methods, ... disease, new research at UT Southwestern Medical Center confirms. ...
... to new treatments, study says , SUNDAY, Aug. 19 ... most red, purple and blue fruits and vegetables, may help ... , In laboratory tests on rats and on human colon ... the growth of colon cancer cells. The team also found ...
... It affected 4 indicators of cardiovascular trouble, study found ... air drags down a number of "biological indicators" pointing ... shows. , The indicators include autonomic dysfunction, inflammation, oxidative ... was published Aug. 15 in the American Journal ...
Cached Medicine News:Health News:Hispanic Teens Take More Skin Cancer Risks 2Health News:Pitt study finds inequality in tobacco advertising 2Health News:Eye-staining technique offers early detection for dry eye syndrome 2Health News:Eye-staining technique offers early detection for dry eye syndrome 3Health News:Urban Smog Tough on Young Adults' Hearts 2
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 31 Millennium Pharmaceuticals, The Takeda,Oncology Company, today ... of VELCADE based therapies that showed consistently high,complete ... multiple,myeloma (MM). CR is one of the best ... for oral presentation at the American Society,of Clinical ...
... reduced the risk of cancer returning or death by 36% beyond clinical ... alone(1) - Findings may allow clinicians to improve standard of care ... ... - These are the first data from a large clinical program exploring ...
Cached Medicine Technology:Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: